Evidence map›Paper›PMID 29881274›Full record

ArticleInternational journal of nanomedicine2018

Cholesteryl oleate-loaded cationic solid lipid nanoparticles as carriers for efficient gene-silencing therapy.

Marc Suñé-Pou, Silvia Prieto-Sánchez, Younes El Yousfi, Sofía Boyero-Corral, Anna Nardi-Ricart, Isaac Nofrerias-Roig, Pilar Pérez-Lozano, Encarna García-Montoya, Montserrat Miñarro-Carmona, Josep Ramón Ticó and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Marc Suñé-PouService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Silvia Prieto-SánchezDepartment of Molecular Biology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Younes El YousfiDepartment of Molecular Biology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Sofía Boyero-CorralDepartment of Molecular Biology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Anna Nardi-RicartService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Isaac Nofrerias-RoigService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Pilar Pérez-LozanoService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Encarna García-MontoyaService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Montserrat Miñarro-CarmonaService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Josep Ramón TicóService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Josep Mª Suñé-NegreService of Development of Medicines (SDM), Faculty of Pharmacy, University of Barcelona, Barcelona, Spain.
Cristina Hernández-MunainDepartment of Cell Biology and Immunology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Carlos SuñéDepartment of Molecular Biology, Institute of Parasitology and Biomedicine "López-Neyra" (IPBLN-CSIC), Granada, Spain.
Duran i Reynals Hospital · ESInstituto de Parasitología y Biomedicina "López - Neyra" · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCationic solid lipid nanoparticles (SLNs) have been given considerable attention for therapeutic nucleic acid delivery owing to their advantages over viral and other nanoparticle delivery systems. However, poor delivery efficiency and complex formulations hinder the clinical translation of SLNs.

aimThe aim of this study was to formulate and characterize SLNs incorporating the cholesterol derivative cholesteryl oleate to produce SLN-nucleic acid complexes with reduced cytotoxicity and more efficient cellular uptake.

methodsFive cholesteryl oleate-containing formulations were prepared. Laser diffraction and laser Doppler microelectrophoresis were used to evaluate particle size and zeta potential, respectively. Nanoparticle morphology was analyzed using electron microscopy. Cytotoxicity and cellular uptake of lipoplexes were evaluated using flow cytometry and fluorescence microscopy. The gene inhibition capacity of the lipoplexes was assessed using siRNAs to block constitutive luciferase expression.

resultsWe obtained nanoparticles with a mean diameter of approximately 150-200 nm in size and zeta potential values of 25-40 mV. SLN formulations with intermediate concentrations of cholesteryl oleate exhibited good stability and spherical structures with no aggregation. No cell toxicity of any reference SLN was observed. Finally, cellular uptake experiments with DNA-and RNA-SLNs were performed to select one reference with superior transient transfection efficiency that significantly decreased gene activity upon siRNA complexation.

conclusionThe results indicate that cholesteryl oleate-loaded SLNs are a safe and effective platform for nonviral nucleic acid delivery.

Indexed as

Gene SilencingCationsCholesterol EstersDrug CarriersElectrophoresisGenetic TherapyHEK293 CellsHumansLasersLipidsMicroscopy, FluorescenceNanoparticlesParticle SizeRNA, Small InterferingTransfectionCationsCholesterol Esterscholesteryl oleateDrug CarriersLipidsRNA, Small Interferingcationic solid lipid nanoparticlescholesteryl oleatecytotoxicityplasmid DNAsiRNASLNstransfectionuptake

Identifiers

PMID29881274
PMCPMC5985802
OpenAlexW2807128827

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.